首页> 外文期刊>International Journal of Probiotics & Prebiotics >A REVIEW OF THE EVIDENCE AVAILABLE FOR THE USE AND EFFECTIVENESS OF PROBIOTIC DRINKS AND SUPPLEMENTS FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME
【24h】

A REVIEW OF THE EVIDENCE AVAILABLE FOR THE USE AND EFFECTIVENESS OF PROBIOTIC DRINKS AND SUPPLEMENTS FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME

机译:肠易激综合征和补品治疗肠易激综合征的可用证据和有效性综述

获取原文
获取原文并翻译 | 示例
           

摘要

Irritable Bowel Syndrome (IBS) is a substantial burden on healthcare systems. There are a plethora of probiotic products on the market that target gastrointestinal problems. This review aims to guide the healthcare practitioner to make an informed judgment when prescribing probiotic products for alleviating the symptoms of IBS, as conventional medication has been found to have a few adverse effects. Six recent systematic reviews and 27 clinical trials were analysed. The microbial content of twelve commercial products was examined. All the extracted evidence was summarised and critically reviewed. The quality of the research was found to be limited and often contradictory. A need for studies of longer duration and of larger sample size was identified. Dosages in clinical trials varied greatly as did the use of multi or single strain products. Two parameters were selected (global improvement and abdominal pain) and probiotic species were scored according to their performance in clinical studies. Lactobacillus rhamnosus scored the highest for improvement of global symptoms and Lactobacillus acidophiphilus scored the highest for improvement of abdominal pain. Probiotics have few adverse effects, and although they may not supply the cure for all the symptoms of IBS, they could provide a way to self manage the condition. The increase in research dedicated to understanding and proving the efficacy of probiotics should mean that before long current inconsistencies in research methods are removed.
机译:肠易激综合症(IBS)是医疗保健系统的一大负担。市场上有许多针对胃肠道问题的益生菌产品。这篇综述旨在指导医疗从业人员在处方益生菌产品缓解IBS症状时做出明智的判断,因为已发现常规药物具有一些不良作用。最近进行了六次系统评价和27项临床试验。检查了十二种商品的微生物含量。对所有提取的证据进行了总结和严格审查。研究的质量被发现是有限的并且经常是矛盾的。确定了需要更长的研究时间和更大的样本量的研究。临床试验中的剂量与使用多菌株或单菌株产品的剂量差异很大。选择两个参数(总体改善和腹痛),并根据益生菌在临床研究中的表现对它们进行评分。鼠李糖乳杆菌在改善总体症状方面得分最高,而嗜酸乳杆菌在改善腹痛方面得分最高。益生菌几乎没有不良反应,尽管它们可能无法治愈IBS的所有症状,但它们可以提供一种自我控制疾病的方法。致力于了解和证明益生菌功效的研究的增加意味着,要消除长期以来研究方法中的矛盾之处。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号